Centene Corporation (CNC)

On our desk, the immediate selloff of 8.1% post-earnings despite a headline EPS beat tells the whole story. The market is questioning the durability of these margins when premium and service revenue growth sits at a modest 3.7% to 4%, and membership counts in Marketplace and Medicaid are contracting. Even though the guidance floor was lifted past $4.80, roughly $0.50 of that is baked from non-recurring settlements. We are advising caution until organic enrollment stabilizes.

Looking at the quantitative profile, CNC looks astonishingly cheap on traditional deep-value metrics, trading at a P/E of roughly 13.11x with a 3Y PEG of 0.28x. Premium repricing and tighter eligibility protocols are successfully driving down the Health Benefits Ratio, pushing Marketplace pre-tax margins toward 4.75% for FY2026. However, prospective buyers need to handicap the H2'26 and 2027 headwinds from OB3 Medicaid shifts before pulling the trigger.

From a healthcare operations perspective, Sarah London and the management team are executing a disciplined turnaround by prioritizing medical cost management over raw volume. Ending Q2 with 12.1 million Medicaid members and holding a Medicaid HBR of 93.9% aligns closely with guidance, proving that localized medical cost controls are successfully offsetting policy-driven membership attrition across state programs.

Our risk management desk is flagging the 8% to 9% expected decline in Medicaid enrollment for 2026. Even though improved state rates have lifted the estimated full-year rate impact to around 5%, the structural membership attrition coupled with tighter eligibility requirements means second-half HBR and adjusted EPS could hit localized air pockets that create a much better entry point down in the low $60s.

As a hedge fund PM tracking government-sponsored healthcare plans, I see the margin recovery as genuinely real, but the street is still catching up. Commercial HBR at 79.2% and a Medicare segment HBR of 89.5% showcase foundational outperformance. If management can deliver on the projected 2027 adjusted EPS of $5.25 and we apply a normalized 17x multiple, a $90 price target becomes entirely realistic from these levels.